Stocks and Investing
Stocks and Investing
Wed, December 16, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (ADCT) at Buy with Increased Target to $56 on, Dec 16th, 2020
Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Increased Target from $52 to $56 on, Dec 16th, 2020.
Matthew has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Konstantinos Aprilakis of "Stifel" Initiated at Hold and Held Target at $42 on, Thursday, December 3rd, 2020
This is the rating of the analyst that currently disagrees with Matthew
- Robert Burns of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $47 on, Thursday, October 29th, 2020
Contributing Sources